Peptide research index Updated 21 Aug 2026
Every compound, on the same terms
One index across 118 compounds and 7 research categories — what has been published, what regulators have recorded, who carries each compound, and at what median price.
Indexed evidenceRegulatory contextProvider availabilityPrice dataNo dosing guidance
Start with a compound
Enter opens the compound’s profile. To narrow the full table instead, use the search in the index below.
- Compounds tracked
- 118Every profile on the same template — no compound gets a different standard.
- With indexed citations
- 101 / 118At least one indexed source on record.
- With price coverage
- 53 / 118An indexed median $/mg from tracked providers.
- Dosing protocols published
- 0By policy, not by gap — this index never publishes dosing or administration guidance.
Browse by research area
Peptide index · 118 compounds
118 compounds
| Official context | Open profile | ||||
|---|---|---|---|---|---|
| 5-Amino-1MQ | 1 | 23 | $2.95 | Status unknown | |
| Ac-SDKP | 3 | not indexed | not indexed | Not evaluated | |
| ACE-031 | 1 | not indexed | $123.97 | Investigational | |
| AICAR | 6 | not indexed | $1.07 | Investigational | |
| Alpha-MSH | 12 | not indexed | not indexed | Not evaluated | |
| Angiotensin (1-7) | 9 | not indexed | not indexed | Investigational | |
| AOD-9604 | 1 | 116 | $10.25 | Compounding nomination withdrawn | |
| ARA-290 | 2 | 6 | $4.80 | Investigational | |
| Argireline | 3 | 16 | not indexed | Not evaluated | |
| BPC-157 | 14 | 405 | $5.25 | Advisory committee recommendedJul 2026 | |
| Cagrilintide | 9 | 6 | $11.36 | InvestigationalCompounding: restricted · Jun 2026 | |
| Carnosine | 8 | 5 | not indexed | Not evaluated | |
| Cartalax | not indexed | 3 | $3.00 | Not evaluated | |
| Cerebrolysin | 5 | 23 | $0.83 | Investigational | |
| Cerluten | 2 | 1 | not indexed | Status unknown | |
| Cetrorelix | 7 | not indexed | not indexed | FDA approved | |
| CGRP | 10 | 2 | not indexed | Not evaluated | |
| Chonluten | 2 | 1 | $3.00 | Not evaluated | |
| CJC-1295 (without DAC) | 3 | 308 | $7.80 | Compounding nomination withdrawn | |
| CJC-1295 DAC | 1 | not indexed | $11.94 | Not evaluated | |
| Cortagen | 2 | not indexed | not indexed | Not evaluated | |
| Cortexin | 1 | 3 | not indexed | Not evaluated | |
| Dalargin | 1 | not indexed | not indexed | Not evaluated | |
| Davunetide | 3 | not indexed | not indexed | Investigational | |
| Desmopressin | 5 | not indexed | not indexed | FDA approved | |
| Dihexa | 2 | 34 | not indexed | Compounding nomination withdrawn | |
| DSIP | 1 | 62 | $5.95 | Advisory committee not recommendedJul 2026 | |
| EGF | 2 | not indexed | not indexed | Not evaluated | |
| Eloralintide | 4 | not indexed | $12.20 | InvestigationalCompounding: restricted · Jul 2026 | |
| Endoluten | 1 | 1 | not indexed | Status unknown | |
| Epithalon | not indexed | 109 | $3.06 | Advisory committee recommendedJul 2026 | |
| FGF-1 | 1 | not indexed | not indexed | Not evaluated | |
| FGL | not indexed | 2 | not indexed | Not evaluated | |
| Follistatin 344 | not indexed | 7 | $119.50 | Not evaluated | |
| Foxo4-DRI | 3 | 5 | $20.75 | Not evaluated | |
| FSH | 9 | not indexed | not indexed | FDA approvedSep 1997 | |
| GHK-Cu | 7 | 233 | $0.70 | Compounding nomination withdrawnCompounding: restricted · Sep 2023 | |
| Ghrelin | 5 | 2 | not indexed | Not evaluated | |
| GHRP-2 | 2 | 22 | $3.87 | Banned from compoundingSep 2023Compounding: restricted · Sep 2023 | |
| GHRP-6 | 1 | 20 | $3.99 | Banned from compoundingSep 2023Compounding: restricted · Sep 2023 | |
| GLP-1 (7-37) | 1 | 21 | not indexed | Not evaluated | |
| GLP-2 | 7 | 4 | $8.33 | Not evaluated | |
| Glutathione | 1 | 108 | not indexed | Not evaluated | |
| Gonadorelin | 3 | 16 | $12.49 | Not evaluated | |
| hCG | 73 | 29 | not indexed | FDA approvedSep 2000 | |
| Hexarelin | 1 | 15 | $8.85 | Not evaluated | |
| HLDF-6 | not indexed | not indexed | not indexed | Not evaluated | |
| Humanin | 5 | 7 | $10.20 | Not evaluated | |
| IGF-1 | 1 | 15 | not indexed | FDA approvedAug 2005 | |
| IGF-1 LR3 | not indexed | 38 | not indexed | Not evaluated | |
| IGF-2 | 6 | not indexed | not indexed | Not evaluated | |
| IGF-DES | not indexed | not indexed | not indexed | Status unknown | |
| Ipamorelin | 5 | 315 | $6.00 | Banned from compoundingSep 2023Compounding: restricted · Sep 2023 | |
| KGF-1 | 1 | not indexed | not indexed | Not evaluated | |
| Kisspeptin-10 | 6 | 34 | $5.39 | Banned from compoundingSep 2023Compounding: restricted · Sep 2023 | |
| Kisspeptin-54 | 5 | 5 | not indexed | Investigational | |
| Klotho | 8 | not indexed | not indexed | Not evaluated | |
| KPV | 3 | 61 | $5.33 | Advisory committee recommendedJul 2026 | |
| Larazotide | 3 | 5 | not indexed | Investigational | |
| Leu-Enkephalin | 2 | not indexed | not indexed | Not evaluated | |
| Leuphasyl | 1 | not indexed | not indexed | Not evaluated | |
| Leuprolide | 8 | 1 | not indexed | FDA approvedApr 1985 | |
| LH | 6 | not indexed | not indexed | FDA approvedOct 2004 | |
| Liraglutide | 8 | 45 | not indexed | FDA approvedJan 2010 | |
| Livagen | 2 | 1 | $3.00 | Not evaluated | |
| LL-37 | 6 | 23 | $9.66 | Compounding nomination withdrawn | |
| Matrixyl | 1 | 10 | not indexed | Not evaluated | |
| Melanotan II | 2 | 49 | $3.96 | Compounding nomination withdrawn | |
| Met-Enkephalin | 2 | 2 | not indexed | Not evaluated | |
| MGF | 6 | 12 | not indexed | Not evaluated | |
| MK-677 | 2 | 38 | not indexed | Banned from compoundingSep 2023Compounding: restricted · Sep 2023 | |
| MOTS-c | 8 | 111 | $4.00 | Advisory committee recommendedJul 2026 | |
| Myostatin Propeptide | 2 | 1 | not indexed | Not evaluated | |
| N-Acetyl Selank | not indexed | 1 | not indexed | Status unknown | |
| N-Acetyl Semax | not indexed | not indexed | not indexed | Status unknown | |
| NAD+ | 4 | 357 | $0.45 | Evaluated, not recommendedSep 2019 | |
| Noopept | 1 | 1 | not indexed | Not evaluated | |
| Ovagen | 1 | 1 | $2.81 | Not evaluated | |
| Oxyntomodulin | 4 | not indexed | not indexed | Investigational | |
| Oxytocin | 8 | 43 | $7.48 | FDA approvedJul 1980 | |
| P21 | 2 | 1 | not indexed | Not evaluated | |
| Palmitoyl Tripeptide-1 | 2 | 3 | not indexed | Not evaluated | |
| PEG-MGF | not indexed | 7 | $17.00 | Compounding nomination withdrawn | |
| Pinealon | 1 | 15 | $3.55 | Not evaluated | |
| Pramlintide | 3 | not indexed | not indexed | FDA approvedMar 2005 | |
| PT-141 | 5 | 212 | $4.35 | FDA approvedJun 2019 | |
| PTD-DBM | not indexed | 6 | not indexed | Not evaluated | |
| Relaxin | 5 | not indexed | not indexed | Investigational | |
| Retatrutide | 10 | 45 | $6.90 | InvestigationalJul 2026Compounding: restricted · Jun 2026 | |
| Retinalamin | 2 | 1 | not indexed | Not evaluated | |
| Rigin | not indexed | 2 | not indexed | Not evaluated | |
| Selank | not indexed | 103 | $4.77 | Compounding nomination withdrawn | |
| Semaglutide | 5 | 681 | $9.00 | FDA approvedJun 2021 | |
| Semax | not indexed | 98 | $4.38 | Advisory committee recommendedJul 2026 | |
| Sermorelin | 3 | 338 | $8.40 | Not evaluated | |
| Sigumir | 1 | 1 | not indexed | Not evaluated | |
| SNAP-8 | not indexed | 8 | $3.40 | Not evaluated | |
| Splenin | 2 | 1 | not indexed | Not evaluated | |
| SS-31 | 10 | 24 | $5.16 | FDA approvedSep 2025 | |
| SYN-AKE | not indexed | not indexed | not indexed | Not evaluated | |
| TB-500 | 3 | 248 | $6.53 | Advisory committee recommendedJul 2026 | |
| TB4-Frag | 2 | 5 | not indexed | Not evaluated | |
| Teduglutide | 8 | not indexed | not indexed | FDA approvedDec 2012 | |
| Teriparatide | 4 | not indexed | not indexed | FDA approvedNov 2002 | |
| Tesamorelin | 7 | 152 | $7.86 | FDA approvedNov 2010 | |
| Testagen | not indexed | not indexed | $2.95 | Not evaluated | |
| Testoluten | 1 | 1 | not indexed | Status unknown | |
| Thymalin | 5 | 3 | $4.35 | Not evaluated | |
| Thymosin Alpha-1 | 2 | 137 | $7.90 | Compounding nomination withdrawn | |
| Thymulin | 11 | 15 | not indexed | Not evaluated | |
| Tirzepatide | 9 | 451 | $5.27 | FDA approvedMay 2022 | |
| TRH | 1 | 1 | not indexed | Not evaluated | |
| Triptorelin | 6 | not indexed | not indexed | FDA approved | |
| Vasopressin | 7 | 3 | not indexed | FDA approvedApr 2014 | |
| Vesugen | 2 | 1 | $3.00 | Not evaluated | |
| Vilon | 1 | 1 | $3.00 | Not evaluated | |
| VIP | 16 | 14 | $7.68 | Not evaluated | |
| Vladonix | 1 | 1 | not indexed | Status unknown |